Avenue Biosciences
Avenue Biosciences helps biopharmaceutical developers increase protein production yields and product quality to make difficult‑to‑express biologics manufacturable. The company uses a proprietary protein engineering platform that combines machine learning and AI with synthetic biology, high‑throughput chemistry, and bioinformatics to optimize N‑terminal signal peptides for mammalian expression systems. Its technology is offered as services for biotech and biopharma customers and is compatible with diverse modalities including mRNA therapies and synthetic proteins. Founded on research from the University of Helsinki and operating between San Francisco and Helsinki, Avenue reduces time‑to‑market and production costs for therapeutic development.
Avenue Biosciences
Avenue Biosciences helps biopharmaceutical developers increase protein production yields and product quality to make difficult‑to‑express biologics manufacturable. The company uses a proprietary protein engineering platform that combines machine learning and AI with synthetic biology, high‑throughput chemistry, and bioinformatics to optimize N‑terminal signal peptides for mammalian expression systems. Its technology is offered as services for biotech and biopharma customers and is compatible with diverse modalities including mRNA therapies and synthetic proteins. Founded on research from the University of Helsinki and operating between San Francisco and Helsinki, Avenue reduces time‑to‑market and production costs for therapeutic development.